1-8 of 8
cabozantinib
Close
Sort by
Journal Articles

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

Sandip Patel, MBBS, Tiffany George, MD, Tzu-Fei Wang, MD MPH, Sherry Mori Vogt, Pharm D, Edmund Folefac, MD, Ming Yin, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3681.
https://doi.org/10.1182/blood-2019-130465
Published: 2019
Journal Articles

Metabolic Alterations May Contribute to Cabozantinib Resistance in Acute Myeloid Leukemia Cells with FLT3 -ITD

Fang-Yu Lo, Kit Man Ng, MS, Wen-Chun Chen, MS, Chung-Yi Hu, PhD, Hsin-An Hou, MD PhD, Cheng-Hong Tsai, MD, M.Sc., Da-Liang Ou, PhD, Hwei-Fang Tien, MD, PhD, Liang-In Lin, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2785.
https://doi.org/10.1182/blood-2018-99-118322
Published: 2018
Journal Articles

Pyrvinium Pamoate Overcomes Cabozantinib-Resistance of FLT3 -ITD AML Cells through Modulating the Mitochondria Functions and Signaling Pathways

Yu-Hsuan Fu, BS, Wen-Hui Lu, MS, Pei-Qi Lan, MS, Chung-Yi Hu, PhD, Chien-Yuan Chen, MD, PhD, Da-Liang Ou, PhD, Hwei-Fang Tien, MD, PhD, Liang-In Lin, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4683.
https://doi.org/10.1182/blood-2018-99-118476
Published: 2018
Journal Articles

Targeting Intracellular Signaling Cascades for Patients with Relapsed, Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

Shehroz Aslam, MD, Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Rida Riaz, MBBS, Seren Durer, MD, Ceren Durer, MD, Faisal Mahfooz, MD, Muhammad Jahanzeb Khalil, MD, Jemin Aby Jose, MD, Zunairah Shah, MBBS, Chaudhry Saad Sohail, MD, Maaz Ahmed Yusufi, MD, Faiz Anwer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5659.
https://doi.org/10.1182/blood-2018-99-115721
Published: 2018
Journal Articles

A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia

Amir T. Fathi, MD, Traci M. Blonquist, MS, Mark J. Levis, MD PhD, Daniela Hernandez, MD, Karen K. Ballen, MD, David E. Avigan, MD, Robin Joyce, MD, Malgorzata McMasters, MD, Emma Logan, Gabriela S. Hobbs, MD, Andrew M. Brunner, MD, Christine Connolly, Ashley M. Perry, BS, Christelle Joseph, Tina T. Som, Aura Y. Ramos, Donna S. Neuberg, ScD, Philip C. Amrein, MD
Journal: Blood
Blood (2016) 128 (22): 5218.
https://doi.org/10.1182/blood.V128.22.5218.5218
Published: 2016
Journal Articles

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma

Clinical Trials & Observations
Nikoletta Lendvai, Andrew J. Yee, Ioanna Tsakos, Aeri Alexander, Sean M. Devlin, Hani Hassoun, Neha Korde, Alexander M. Lesokhin, Heather Landau, Sham Mailankody, Guenther Koehne, David J. Chung, Ola Landgren, Noopur S. Raje, Sergio Giralt
Journal: Blood
Blood (2016) 127 (19): 2355–2356.
https://doi.org/10.1182/blood-2016-01-694786
Published: 2016
Journal Articles

Effects of Cabozantinib Alone and in Combination with Bortezomib in the 5TGM1 Murine Multiple Myeloma Model

Dana T. Aftab, PhD, Mari I. Suominen, Douglas O. Clary, PhD, Rami Käkönen, Katja M. Fagerlund, Esa Alhoniemi, Jukka P. Rissanen, Jussi M. Halleen
Journal: Blood
Blood (2014) 124 (21): 3442.
https://doi.org/10.1182/blood.V124.21.3442.3442
Published: 2014
Journal Articles

Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling

Jarno Kivioja, MSc, Mika Kontro, MD, Angeliki Thanasopoulou, PhD, Muntasir Mamun Majumder, MSc,BPharm, Bhagwan Yadav, MSc, Heikki Kuusanmäki, MSc, Alun Parsons, MSc, Juerg Schwaller, MD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2014) 124 (21): 2160.
https://doi.org/10.1182/blood.V124.21.2160.2160
Published: 2014